Ischemic Central Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Ischemic Central Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-08-14Clinical Trial Update: Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) [Phase 1]
Phase 1 RAVE2 trial evaluating 2.0 mg ranibizumab for ischemic central retinal vein occlusion was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2016-10-31Clinical Trial Update: Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG [Phase 2, Phase 3]
Clinical trial update on Aganirsen for ischemic central retinal vein occlusion patients at risk of neovascular glaucoma, involving Phase 2 a…
-
CLINICAL_TRIALS trial_result · 2013-03-14Clinical Trial Update: Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion [Phase 1]
Phase 1 trial of Rubeosis Anti-VEGF (RAVE) for ischemic central retinal vein occlusion has completed.